95 research outputs found
Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules
Peer reviewe
A crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO)
Rationale Mandibular advancement devices (MADs)
are used to treat obstructive sleep apnoea-hypopnoea
syndrome (OSAHS) but evidence is lacking regarding
their clinical and cost-effectiveness in less severe disease.
Objectives To compare clinical- and cost-effectiveness
of a range of MADs against no treatment in mild to
moderate OSAHS.
Measurements and methods This open-label,
randomised, controlled, crossover trial was undertaken at
a UK sleep centre. Adults with Apnoea-Hypopnoea Index
(AHI) 5–<30/h and Epworth Sleepiness Scale (ESS) score
≥9 underwent 6 weeks of treatment with three nonadjustable
MADs: self-moulded (SleepPro 1; SP1);
semi-bespoke (SleepPro 2; SP2); fully-bespoke MAD
(bMAD); and 4 weeks no treatment. Primary outcome
was AHI scored by a polysomnographer blinded to
treatment. Secondary outcomes included ESS, quality of
life, resource use and cost.
Main results 90 patients were randomised and 83
were analysed. All devices reduced AHI compared with
no treatment by 26% (95% CI 11% to 38%, p=0.001)
for SP1, 33% (95% CI 24% to 41%) for SP2 and 36%
(95% CI 24% to 45%, p<0.001) for bMAD. ESS was
1.51 (95% CI 0.73 to 2.29, p<0.001, SP1) to 2.37
(95% CI 1.53 to 3.22, p<0.001, bMAD) lower than no
treatment (p<0.001 for all). Compliance was lower for
SP1, which was the least preferred treatment at trial exit.
All devices were cost-effective compared with no
treatment at a £20 000/quality-adjusted life year (QALY)
threshold. SP2 was the most cost-effective up to
£39 800/QALY.
Conclusions Non-adjustable MADs achieve clinically
important improvements in mild to moderate OSAHS and
are cost-effective
In-home evaluation of efficacy and titration of a mandibular advancement device for obstructive sleep apnea
There is increasing evidence that mandibular advancement devices (MADs) can be an effective treatment for some patients with obstructive sleep apnea, a highly prevalent chronic disease. In this study, the objectives were to objectively assess the effectiveness of MAD therapy using a limited channel recorder, and to develop a model for identifying patients who may be appropriate for MAD therapy as the initial treatment option. Thirty patients were prospectively recruited and studied at two independent dentist offices and the participants’ homes. Subjects wore the ARES Unicorder for two nights before insertion of the MAD, and again when the dentist determined that the patient had reached the titration endpoint. Self-reported measures of depression, sleepiness, and quality of life were obtained pre- and posttreatment. The reviewer was blinded to the study status while the physiological signals were being visually inspected. Significant reductions in the apnea/hypopnea index (AHI), hypoxemia measures, and snoring level were observed posttreatment. Twenty-seven of the 30 (90%) patients had a posttreatment AHI (using a 4% desaturation for hypopneas) below a clinical cut-off of 10. All but one patient (97%) exhibited at least a 50% decrease in AHI or had a posttreatment AHI ≤ 10. Significant differences in body mass index, weight, and neck circumference in patients with posttreatment AHIs above and below a clinical cut-off of five were identified. The linear regression used to predict the posttreatment AHI using pretreatment data resulted in an R2 of 0.68. The model correctly predicted two patients who were unable to obtain a posttreatment AHI of 10 or less. This study was designed to demonstrate two models of collaboration between a dental sleep medicine specialist and a sleep medicine physician in the monitoring of a patient treated with a MAD. The outcome data suggest that the limited channel recording system can be used as an alternative to laboratory polysomnography to reduce the cost of MAD treatment, and to improve the quality and consistency of posttreatment patient care
Predictors of success for mandibular repositioning appliance in obstructive sleep apnea syndrome
Evidence for dental and dental specialty treatment of obstructive sleep apnoea. Part 1: the adult OSA patient and Part 2: the paediatric and adolescent patient
Until recently, obstructive sleep apnoea was a largely unknown condition. Because of the well-publicised death of some high-profile people resulting from untreated obstructive sleep apnoea, now mostly everyone has heard of the condition. Following diagnosis, several medical treatment modalities are available to patients. However, the role that dentistry and its various specialties can play in successful treatment for obstructive sleep apnoea should not be overlooked. The common causes for adult and paediatric obstructive sleep apnoea will be presented as well as a review of the more successful forms of dental treatment. Finally, a summary of the current evidence regarding obstructive sleep apnoea treatment will be presented.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79355/1/j.1365-2842.2010.02136.x.pd
Short-term efficacy of mandibular advancement splint in treatment of obstructive sleep apnea-hypopnea syndrome
Retention of mandibular advancement devices in the treatment of obstructive sleep apnea: an in vitro pilot study
Treatment of obstructive sleep apnea using a custom-made titratable duobloc oral appliance: a prospective clinical study
Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea–hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure
Beyond communities and populations: organizational groups and the case of UK university spinoffs
- …